B. Riley Cuts Geron (NASDAQ:GERN) Price Target to $3.50

Geron (NASDAQ:GERN) had its target price cut by equities research analysts at B. Riley from $5.50 to $3.50 in a note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. B. Riley’s target price would suggest a potential upside of 37.80% from the company’s current price. B. Riley also issued estimates for Geron’s FY2027 earnings at $0.28 EPS.

GERN has been the topic of a number of other reports. Needham & Company LLC lifted their price target on Geron from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Monday, January 13th. Barclays raised Geron to a “strong-buy” rating in a research note on Friday, November 29th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Geron in a research note on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Geron currently has a consensus rating of “Moderate Buy” and a consensus price target of $6.91.

Geron Stock Performance

Shares of GERN stock opened at $2.54 on Tuesday. The business’s 50-day moving average price is $3.16 and its 200-day moving average price is $3.89. Geron has a 12 month low of $1.64 and a 12 month high of $5.34. The firm has a market capitalization of $1.54 billion, a price-to-earnings ratio of -7.94 and a beta of 0.53. The company has a current ratio of 2.89, a quick ratio of 2.74 and a debt-to-equity ratio of 0.04.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Alternative Investment Advisors LLC. boosted its position in Geron by 13.3% in the third quarter. Alternative Investment Advisors LLC. now owns 22,209 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 2,612 shares during the last quarter. Rovin Capital UT ADV lifted its position in shares of Geron by 26.9% during the 4th quarter. Rovin Capital UT ADV now owns 17,270 shares of the biopharmaceutical company’s stock valued at $61,000 after buying an additional 3,660 shares during the last quarter. Values First Advisors Inc. lifted its position in shares of Geron by 13.6% during the 3rd quarter. Values First Advisors Inc. now owns 30,674 shares of the biopharmaceutical company’s stock valued at $139,000 after buying an additional 3,668 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Geron by 23.1% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,802 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 4,094 shares during the last quarter. Finally, Xponance Inc. lifted its position in shares of Geron by 12.9% during the 4th quarter. Xponance Inc. now owns 42,401 shares of the biopharmaceutical company’s stock valued at $150,000 after buying an additional 4,829 shares during the last quarter. Hedge funds and other institutional investors own 73.71% of the company’s stock.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.